ENDRA Life Sciences Inc.

Listed Company

NDRACIK 0001681682NasdaqEmerging GrowthElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-7.03M

Total Assets

$3.85M

Equity

$2.26M

Shares Out

1.27M

Op. Cash Flow

$-5.18M

NDRA$4.85−34.01% · past yearDBEQ Basic

Daily closing prices

Business

ENDRA Life Sciences Inc. develops Thermo-Acoustic Enhanced Ultrasound (TAEUS), a next-generation ultrasound technology platform for non-invasive assessment of liver fat and metabolic diseases. The company's initial product is a TAEUS liver device designed to interface with conventional ultrasound systems to quantify liver fat content. ENDRA targets pharmaceutical companies, CROs, high-end primary care networks, bariatric and metabolic clinics, and primary and internal medicine practices through subscription-based recurring revenue, capital equipment sales, and service offerings.

Summary from 10-K filed 2026-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	2	3	5	7	5
Sales and marketing	189,470	571,040	820,554	1	1
General and administrative	4	7	5	5	5
Total operating expenses	6	11	11	13	11
Operating loss	−6	−11	−11	−13	−11
Other income	71,224	108,484	460,485	—	—
Digital asset staking compensation	5,121	—	—	—	—
Change in fair value of digital assets	−995,161	—	—	—	—
Warrant expense	−665,030	−7	—	—	—
Changes in fair value of warrant liability	319,537	3	—	—	—
Gain on settlement of warrant exercise	—	3	—	—	—
Total other expenses	−1	−690,800	460,485	−21,533	267,055
Loss from operations before income taxes	−7	−12	−10	−13	−11
Provision for income taxes	—	—	0	0	0
Net Loss	−7	−12	−10	−13	−11
Net loss per share basic (in Dollars per share)	−8.93	−56.94	—	−4.56	−5.55
Net loss per share diluted (in Dollars per share)	−8.93	−56.94	−2,767	—	—
Weighted average common shares basic (in Shares)	787,020	202,106	—	—	—
Weighted average common shares diluted (in Shares)	787,020	202,106	3,636	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	762,365	3	—	5	9
Prepaid expenses	205,604	204,185	198,905	490,299	1
Total Current Assets	967,969	3	3	5	12
Fixed assets, net	42,516	69,281	111,782	235,655	131,130
Right of use assets	461,949	578,013	354,091	505,816	643,413
Prepaid expenses, long term	365,417	365,417	626,610	502,576	—
Digital Assets	2	—	—	—	—
Other assets	5,986	5,986	—	5,986	5,986
Total Assets	4	4	7	9	13
Accounts payable and accrued liabilities	621,578	508,293	700,754	2	—
Lease liabilities, current portion	129,378	96,937	173,857	152,228	132,330
Total Current Liabilities	750,956	605,230	903,095	2	2
Lease liabilities	362,974	487,482	192,062	365,919	518,147
Warrant Liability	479,747	799,284	—	—	—
Total Long Term Debt	842,721	1	192,062	365,919	—
Total Liabilities	2	2	1	2	2
Commitments and Contingencies	—	—	—	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 1,176,477 and 536,908 shares issued and outstanding, respectively	116	53	1	317	212
Additional paid in capital	113	106	98	89	79
Stock payable	—	—	5,233	6,073	13,863
Accumulated deficit	−110	−103	−92	−82	−69
Total Stockholders Equity	2	3	6	7	11
Total Liabilities and Stockholders Equity	4	4	7	9	13

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	44,045	46,489	—	96,661	116,238
Fixed assets write off	—	8,808	—	—	—
Inventory reserve	—	2	—	—	—
Stock compensation expense	329,409	571,924	996,430	1	1
Amortization of right of use assets	113,249	159,683	151,725	137,597	108,177
Fair value of vested advisory warrant	665,030	—	—	—	—
Warrant Expense	—	7	—	—	—
Decrease/(increase) in prepaid expenses	−1,419	255,913	167,360	355,128	−957,203
Decrease in inventory	—	235,731	−116,193	−1	−694,958
Increase/(decrease) in accounts payable and accrued liabilities	113,287	−198,867	−822,258	111,575	491,104
Decrease in lease liability	−89,252	−158,698	−152,228	−132,330	−100,338
Net cash used in operating activities	−5	−7	−10	−13	−11
Purchases of fixed assets	−17,280	−16,000	−33,884	−202,577	−45,000
Proceeds from sale of fixed assets	—	3,204	—	—	—
Purchase of Digital Intangible Assets	−3	—	—	—	—
Net cash used in investing activities	−3	−12,796	−24,721	−202,577	−45,000
Proceeds from fundraising activities	5	1	—	—	—
Proceeds from issuance of common stock for cash	1	5	6	8	11
Proceeds from issuance of common stock for cashless warrant exercise -	—	1	1	0	—
Repayment of loan	—	−28,484	—	—	—
Net cash provided by financing activities	6	8	8	8	13
Net increase (decrease) in cash	−2	395,573	−2	−5	2
Interest paid	55,848	31,910	44,985	59,113	57,655
Income tax paid	—	—	0	0	—
Stock dividend payable	—	−5,233	840	7,790	−3,068
Right of use asset	461,949	578,013	—	—	—
Lease liability	492,352	584,419	—	—	—
Cashless warrants	—	3	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ENDRA Life Sciences Inc.'s CIK number?

ENDRA Life Sciences Inc.'s SEC CIK number is 0001681682 (1681682). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ENDRA Life Sciences Inc.'s SEC filings?

All of ENDRA Life Sciences Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ENDRA Life Sciences Inc. last report earnings?

ENDRA Life Sciences Inc. (NDRA) most recently filed an earnings 8-K with the SEC on Mar 31, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-037497). This is ENDRA Life Sciences Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is ENDRA Life Sciences Inc.'s most recent earnings 8-K?

ENDRA Life Sciences Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 31, 2026 under accession 0001213900-26-037497. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ENDRA Life Sciences Inc.'s latest earnings 8-K →
Look up any company's CIK number →